Topical cyclosporine a 0.05% for the treatment of dry eye disease

Abstract EN

Dry eye disease (DED) is a common clinical condition that challenges ophthalmologists.

topical cyclosporine a is an anti-inflammatory therapy being approved by the food and drug administration (FDA) for the therapy for DED.

this study aimed to evaluate the efficacy and pa-tient tolerability of topical Cyclosporine A 0.05% for the treatment of DED.

A total of 87 patients diagnosed with DED were included in this study.

dry eye symptoms (foreign body sensation, burn-ing, and pain) were scored.

as a baseline measurement, the tear break-up time test (TBUT) and the schirmer‟s test were performed for all the patients.

cyclosporine a 0.05% was given topically twice daily to all the patients for four months.

they were followed up every month for a period of four months.

the clinical signs (Schirmer‟s test, the TBUT), and the symptoms scores, were record-ed for each visit.

the mean age of the patients was 57.25±9.70 years (Range 32 - 80 years); 25 males (28.7%) and 62 females (71.3%).

out of them, 23 (26.4%) cases had Sjögren‟s syndrome, and 12 (13.7%) cases had previous LASIK (laser in-situ keratomileusis).

The symptoms score of the cases improved from (4.95±1.73) pretreatment to (0.40±.70) four months after treatment (P <0.001).

the schirmer‟s test results improved from (4.10 ±1.089) pretreatment to (10.80±2.40) four months post-treatment (P <0.0001), and the TBUT test results improved from (5.54±1.77 s) pre-treatment to (12.95±3.12 s) four months post-treatment (P <0.0001).

Only seven patients (8%) de-veloped ocular side effects in the form of redness, pain, and systemic side effects in the form of headache.

in conclusion, cyclosporine a 0.05% eye drops is an effective treatment for DED, im-proving both signs and symptoms of DED with few ocular side effects.